Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib weekend versus alternate-day maintenance therapy for atopic dermatitis
ChiCTR2200066627Phase 4Not yet recruiting
- Sponsor
- The Eighth Affiliated Hospital of Sun Yat-sen University (Futian, Shenzhen)
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of upadacitinib in atopic dermatitis (AD) (2 arms), sponsored by The Eighth Affiliated Hospital of Sun Yat-sen University (Futian, Shenzhen). Primary endpoint: EASI-90 response at 21 weeks. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2200066627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066627.